Cargando…

Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies

Patients with lymphoproliferative disorders, candidate to autologous stem cell transplantation (ASCT), require mobilization with chemotherapy and granulocyte colony -stimulating factor (G-CSF). This study looked for differences in hematopoietic peripheral stem cells (HPSCs) mobilization in response...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ria, Roberto, Reale, Antonia, Melaccio, Assunta, Racanelli, Vito, Dammacco, Franco, Vacca, Angelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412650/ https://www.ncbi.nlm.nih.gov/pubmed/24722996 http://dx.doi.org/10.1007/s10238-014-0282-9

Ejemplares similares

Neutropenia and G-CSF in lymphoproliferative diseases
por: Ria, Roberto, et al.
Publicado: (2013)

PB2416: EFFICACY AND SAFETY OF BIOSIMILAR PEGFILGRASTIM AFTER AUTOLOGOUS STEM CELL TRANSPLANT: A COMPARATIVE STUDY WITH BIOSIMILAR FILGRASTIM, LENOGRASTIM AND ORIGINATOR PEGFILGRASTIM
por: Marchesi, Francesco, et al.
Publicado: (2023)

Functional and Biological Role of Endothelial Precursor Cells in Tumour Progression: A New Potential Therapeutic Target in Haematological Malignancies
por: Reale, Antonia, et al.
Publicado: (2016)

Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
por: Ria, Roberto, et al.
Publicado: (2020)

The Safety Profile of Filgrastim and Pegfilgrastim
por: Neumann, Theresa A., et al.
Publicado: (2011)

Monocentric Analysis of the Effectiveness and Financial Consequences of the Use of Lenograstim versus Filgrastim for Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma and Myeloma Receiving Chemotherapy and Autologous Stem Cell Transplantation
por: Restelli, Umberto, et al.
Publicado: (2020)

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey
por: Innocenti, Rolando, et al.
Publicado: (2018)

Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors
por: Farhan, Roiya, et al.
Publicado: (2017)

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey [Corrigendum]
Publicado: (2019)

Common Variable Immunodeficiency and Gastric Malignancies
por: Leone, Patrizia, et al.
Publicado: (2018)

Filgrastim XM02 (Tevagrastim®) after autologous stem cell transplantation compared to lenograstim: favourable cost-efficacy analysis
por: Gardellini, A, et al.
Publicado: (2013)

Right Heart Changes Impact on Clinical Phenotype of Amyloid Cardiac Involvement: A Single Centre Study
por: Cicco, Sebastiano, et al.
Publicado: (2020)

Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model
por: Scholz, Markus, et al.
Publicado: (2009)

Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance
por: Melaccio, Assunta, et al.
Publicado: (2022)

Chemotherapy-Induced Neutropenia in HIV Positive Patients with Lymphoma: Comparison of Pegfilgrastim with Daily Filgrastim Administration
por: Teofili, Luciana, et al.
Publicado: (2012)

Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database
por: Rastogi, Shruti, et al.
Publicado: (2022)

MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance
por: Desantis, Vanessa, et al.
Publicado: (2020)

Evidence for Bone Marrow Adult Stem Cell Plasticity: Properties, Molecular Mechanisms, Negative Aspects, and Clinical Applications of Hematopoietic and Mesenchymal Stem Cells Transdifferentiation
por: Catacchio, Ivana, et al.
Publicado: (2013)

Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update
por: Ria, Roberto, et al.
Publicado: (2018)

Gene expression profiling of normal thyroid tissue from patients with thyroid carcinoma
por: Ria, Roberto, et al.
Publicado: (2016)

Autoimmune uveitis: a retrospective analysis of 104 patients from a tertiary reference center
por: Prete, Marcella, et al.
Publicado: (2014)

Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization
por: Awan, Farrukh T., et al.
Publicado: (2012)

Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events
por: Bond, T Christopher, et al.
Publicado: (2017)

Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study
por: Rossi, Luigi, et al.
Publicado: (2013)

Pegfilgrastim Versus Filgrastim for Primary Prophylaxis of Febrile Neutropenia in Patients with non-Hodgkin’s Lymphoma: A Cost-Effectiveness Study
por: Ravangard, Ramin, et al.
Publicado: (2017)

Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review
por: Gebremariam, Girma Tekle, et al.
Publicado: (2022)

Innovator Filgrastim versus Generic Filgrastim in Hematopoietic Stem Cell Transplantation Mobilization
por: Husian, Sadik, et al.
Publicado: (2021)

A randomized, double‐blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma
por: Kubo, Kohmei, et al.
Publicado: (2016)

Comparing the efficacy and side-effects of PDLASTA® (Pegfilgrastim) with PDGRASTIM® (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial
por: Najafi, Safa, et al.
Publicado: (2021)

Antibody V(h) Repertoire Differences between Resolving and Chronically Evolving Hepatitis C Virus Infections
por: Racanelli, Vito, et al.
Publicado: (2011)

A Randomized, Non-Inferiority Study Comparing Efficacy and Safety of a Single Dose of Pegfilgrastim versus Daily Filgrastim in Pediatric Patients after Autologous Peripheral Blood Stem Cell Transplant
por: Cesaro, Simone, et al.
Publicado: (2013)

Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study (KMM122)
por: Jung, Eun Hee, et al.
Publicado: (2023)

Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma
por: Lamanuzzi, Aurelia, et al.
Publicado: (2018)

Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices
por: Morrison, Vicki A., et al.
Publicado: (2007)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2020)

Proteolytic Activity of Human Lymphoid Tumor Cells. Correlation with Tumor Progression
por: Vacca, Angelo, et al.
Publicado: (2000)

Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics
por: Sörgel, Fritz, et al.
Publicado: (2015)

The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements
por: Dammacco, Franco, et al.
Publicado: (2022)

Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma
por: Ria, Roberto, et al.
Publicado: (2012)

Angiogenesis and Progression in Human Melanoma
por: Ria, R., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_eqjjq0185k618avdb87nmo7sog